Laurence Moureau-Zabotto

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat et al. · The Lancet Oncology · 2019 · 469 citations · Full text

Radiation Medicine, Radiation Therapy, Medicine +10

Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma

Laurence Moureau-Zabotto, E. Touboul, D. Lerouge et al. · International Journal of Radiation Oncology*Biology*Physics · 2005 · 132 citations

Positron Emission Tomography, Esophageal Cancer, Medical Imaging +9

Effect on Survival of Local Ablative Treatment of Metastases from Sarcomas: A Study of the French Sarcoma Group

Alexander T. Falk, Laurence Moureau-Zabotto, M. Ouali et al. · Clinical Oncology · 2014 · 96 citations

Surgical Oncology, Malignant Disease, Local Ablative Treatment +8

Predictive Factors of Tumor Response After Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer

Laurence Moureau-Zabotto, B. Farnault, Cécile de Chaisemartin et al. · International Journal of Radiation Oncology*Biology*Physics · 2010 · 80 citations

Tumor Response, Neoadjuvant Chemoradiation, Radiation Therapy +10

Neoadjuvant 5 Fluorouracil-Cisplatin Chemoradiation Effect on Survival in Patients with Resectable Pancreatic Head Adenocarcinoma: A Ten-Year Single Institution Experience

Olivıer Turrini, F. Viret, Laurence Moureau-Zabotto et al. · Oncology · 2009 · 66 citations